OMAN DIABETES DRUGS MARKET Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Oman Diabetes Drugs Market is Segmented Into Drugs (insulin Drugs (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, And Biosimilar Insulins), Oral Anti-Diabetic Drugs (Biguanides, Alpha-glucosidase Inhibitors, Dopamine D2 Receptor Agonist, Sglt-2 Inhibitors, Dpp-4 Inhibitors, Sulfonylureas, And Meglitinides), Non-insulin Injectable Drugs (GLP-1 Receptor Agonists and Amylin Analogue), And Combination Drugs (insulin Combinations and Oral Combinations)). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

OMAN DIABETES DRUGS MARKET Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Oman Diabetes Drugs Market Size

View Global Report
Oman Diabetes Drugs Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
Market Size (2025) USD 226.29 Million
Market Size (2030) USD 311.64 Million
CAGR (2025 - 2030) 6.61 %

Major Players

Oman Diabetes Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Oman Diabetes Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Oman Diabetes Drugs Market Analysis

The Oman Diabetes Drugs Market size is estimated at USD 226.29 million in 2025, and is expected to reach USD 311.64 million by 2030, at a CAGR of 6.61% during the forecast period (2025-2030).

Diabetic drugs are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Diabetic drugs are commonly used to manage diabetes. Diabetic drugs have been potential candidates for treating diabetic patients affected by SARS-CoV-2 infection during the COVID-19 pandemic. Although the current numbers show that the existence of diabetes is comparatively lesser in Oman, the growth rate of the diabetic population is projected to be higher in the country. 

According to Mordor Intelligence, the diabetic population in Oman is expected to reach 0.84 million by 2027. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the country and is one of the leading causes of premature death, morbidity, and loss of economic growth.

Oman, Ministry of Health, recently participated in the virtual launch of the WHO Global Diabetes Compact, organized jointly by the World Health Organization and the government of Canada aimed at raising awareness level about diabetes as a global disease, in addition to expanding prevention and treatment as part of primary health care and universal health coverage.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Oman Diabetes Drugs Industry Overview

The Oman Diabetes Drugs Market is consolidated, with major manufacturers, namely Eli Lilly, Sanofi, Novo Nordisk, AstraZeneca, and other generic players, holding a presence in the region. A major share of the market is held by manufacturers concomitant with strategy-based M&A operations and constantly entering the market to generate new revenue streams and boost existing ones.

Oman Diabetes Drugs Market Leaders

  1. AstraZeneca

  2. Boehringer Ingelheim

  3. Novo Nordisk A/S

  4. Sanofi Aventis

  5. Eli Lilly and Company

  6. *Disclaimer: Major Players sorted in no particular order
Oman Diabetes Drugs Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Oman Diabetes Drugs Market News

  • November 2023: Novo Nordisk's initiation of a Phase III comparative trial for their pipeline drug CagriSema against the recently approved Zepbound suggests the potential for direct competition between the two drugs upon Novo Nordisk's candidate entering the market.
  • October 2022: The Ministry of Industry and Advanced Technology announced the signing of a pair of memoranda of understanding worth AED 260 million (USD 70.8 million) between major pharmaceutical and medical device companies in the UAE. The partnerships align with the National Strategy for Industry and Advanced Technology and the ICV Program. It aims to attract investors and manufacturers to the UAE's pharmaceutical and medical equipment sectors. Under a separate MoU, PureHealth, and Gulf Pharmaceutical Industries Company will establish the first factory in the Middle East to produce Glargine to treat diabetes.

Oman Diabetes Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
  • 4.3 Market Restraints
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products and Services
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

  • 5.1 Insulins
    • 5.1.1 Basal or Long Acting Insulins
    • 5.1.1.1 Lantus (Insulin Glargine)
    • 5.1.1.2 Levemir (Insulin Detemir)
    • 5.1.1.3 Toujeo (Insulin Glargine)
    • 5.1.1.4 Tresiba (Insulin Degludec)
    • 5.1.1.5 Basaglar (Insulin Glargine)
    • 5.1.2 Bolus or Fast Acting Insulins
    • 5.1.2.1 NovoRapid/Novolog (Insulin Aspart)
    • 5.1.2.2 Humalog (Insulin Lispro)
    • 5.1.2.3 Apidra (Insulin Glulisine)
    • 5.1.3 Traditional Human Insulins
    • 5.1.3.1 Novolin/Actrapid/Insulatard
    • 5.1.3.2 Humulin
    • 5.1.3.3 Insuman
    • 5.1.4 Biosimilar Insulins
    • 5.1.4.1 Insulin Glargine Biosimilars
    • 5.1.4.2 Human Insulin Biosimilars
  • 5.2 Oral Anti-diabetic drugs
    • 5.2.1 Biguanides
    • 5.2.1.1 Metformin
    • 5.2.2 Alpha-Glucosidase Inhibitors
    • 5.2.2.1 Alpha-Glucosidase Inhibitors
    • 5.2.3 Dopamine D2 receptor agonist
    • 5.2.3.1 Bromocriptin
    • 5.2.4 SGLT-2 inhibitors
    • 5.2.4.1 Invokana (Canagliflozin)
    • 5.2.4.2 Jardiance (Empagliflozin)
    • 5.2.4.3 Farxiga/Forxiga (Dapagliflozin)
    • 5.2.4.4 Suglat (Ipragliflozin)
    • 5.2.5 DPP-4 inhibitors
    • 5.2.5.1 Onglyza (Saxagliptin)
    • 5.2.5.2 Tradjenta (Linagliptin)
    • 5.2.5.3 Vipidia/Nesina(Alogliptin)
    • 5.2.5.4 Galvus (Vildagliptin)
    • 5.2.6 Sulfonylureas
    • 5.2.6.1 Sulfonylureas
    • 5.2.7 Meglitinides
    • 5.2.7.1 Meglitinides
  • 5.3 Non-Insulin Injectable drugs
    • 5.3.1 GLP-1 receptor agonists
    • 5.3.1.1 Victoza (Liraglutide)
    • 5.3.1.2 Byetta (Exenatide)
    • 5.3.1.3 Bydureon (Exenatide)
    • 5.3.1.4 Trulicity (Dulaglutide)
    • 5.3.1.5 Lyxumia (Lixisenatide)
    • 5.3.2 Amylin Analogue
    • 5.3.2.1 Symlin (Pramlintide)
  • 5.4 Combination drugs
    • 5.4.1 Insulin combinations
    • 5.4.1.1 NovoMix (Biphasic Insulin Aspart)
    • 5.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
    • 5.4.1.3 Xultophy (Insulin Degludec and Liraglutide)
    • 5.4.2 Oral Combinations
    • 5.4.2.1 Janumet (Sitagliptin and Metformin)

6. MARKET INDICATORS

  • 6.1 Type-1 Diabetic Population
  • 6.2 Type-2 Diabetic Population

7. COMPETITIVE LANDSCAPE

  • 7.1 COMPANY PROFILES
    • 7.1.1 Novo Nordisk A/S
    • 7.1.2 Takeda
    • 7.1.3 Pfizer
    • 7.1.4 Eli Lilly
    • 7.1.5 Janssen Pharmaceuticals
    • 7.1.6 Astellas
    • 7.1.7 Boehringer Ingelheim
    • 7.1.8 Merck and Co.
    • 7.1.9 AstraZeneca
    • 7.1.10 Bristol Myers Squibb
    • 7.1.11 Julphar
    • 7.1.12 Novartis
    • 7.1.13 Sanofi Aventis
  • *List Not Exhaustive
  • 7.2 COMPANY SHARE ANALYSIS
    • 7.2.1 Novo Nordisk A/S
    • 7.2.2 Sanofi Aventis
    • 7.2.3 Eli Lilly
    • 7.2.4 Merck and Co.
    • 7.2.5 Others

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Oman Diabetes Drugs Industry Segmentation

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Oman Diabetes Drugs Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.

Insulins Basal or Long Acting Insulins Lantus (Insulin Glargine)
Levemir (Insulin Detemir)
Toujeo (Insulin Glargine)
Tresiba (Insulin Degludec)
Basaglar (Insulin Glargine)
Bolus or Fast Acting Insulins NovoRapid/Novolog (Insulin Aspart)
Humalog (Insulin Lispro)
Apidra (Insulin Glulisine)
Traditional Human Insulins Novolin/Actrapid/Insulatard
Humulin
Insuman
Biosimilar Insulins Insulin Glargine Biosimilars
Human Insulin Biosimilars
Oral Anti-diabetic drugs Biguanides Metformin
Alpha-Glucosidase Inhibitors Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist Bromocriptin
SGLT-2 inhibitors Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas Sulfonylureas
Meglitinides Meglitinides
Non-Insulin Injectable drugs GLP-1 receptor agonists Victoza (Liraglutide)
Byetta (Exenatide)
Bydureon (Exenatide)
Trulicity (Dulaglutide)
Lyxumia (Lixisenatide)
Amylin Analogue Symlin (Pramlintide)
Combination drugs Insulin combinations NovoMix (Biphasic Insulin Aspart)
Ryzodeg (Insulin Degludec and Insulin Aspart)
Xultophy (Insulin Degludec and Liraglutide)
Oral Combinations Janumet (Sitagliptin and Metformin)
Need A Different Region or Segment?
Customize Now

Oman Diabetes Drugs Market Research FAQs

How big is the Oman Diabetes Drugs Market?

The Oman Diabetes Drugs Market size is expected to reach USD 226.29 million in 2025 and grow at a CAGR of 6.61% to reach USD 311.64 million by 2030.

What is the current Oman Diabetes Drugs Market size?

In 2025, the Oman Diabetes Drugs Market size is expected to reach USD 226.29 million.

Who are the key players in Oman Diabetes Drugs Market?

AstraZeneca, Boehringer Ingelheim, Novo Nordisk A/S, Sanofi Aventis and Eli Lilly and Company are the major companies operating in the Oman Diabetes Drugs Market.

What years does this Oman Diabetes Drugs Market cover, and what was the market size in 2024?

In 2024, the Oman Diabetes Drugs Market size was estimated at USD 211.33 million. The report covers the Oman Diabetes Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Oman Diabetes Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Oman Diabetes Drugs Industry Report

Statistics for the 2025 Oman Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Oman Diabetes Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.

Oman Diabetes Drugs Market Report Snapshots